



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
✉ production.office@frontiersin.org

RECEIVED 15 November 2023

ACCEPTED 15 November 2023

PUBLISHED 07 December 2023

CITATION

Frontiers Production Office (2023) Erratum:
PDGF, NGF, and EGF as main
contributors to tumorigenesis in
high-risk retinoblastoma.
Front. Oncol. 13:1339187.
doi: 10.3389/fonc.2023.1339187

COPYRIGHT

© 2023 Frontiers Production Office. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Erratum: PDGF, NGF, and EGF as main contributors to tumorigenesis in high-risk retinoblastoma

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

retinoblastoma - epigenetics, retinoblastoma, PDGF = platelet-derived growth factor, MAPK/ERK2 pathway 1, pediatric cancer and oncology, biomarkers, targeted therapy, growth factors (angiogenesis factors)

An Erratum on

PDGF, NGF, and EGF as main contributors to tumorigenesis in high-risk retinoblastoma

By Al-Ghazzawi K, Wessolly M, Dalbah S, Ketteler P, Kiefer T, Bechrakis N, Leyla J, Ting S, Biewald E and Mairinger FD (2023) *Front. Oncol.* 13:1144951. doi: 10.3389/fonc.2023.1144951

Due to a production error, section **3.2 Anaplastic grade** included two empty subsections: **3.2.1 Undifferentiated retinoblastoma** and **3.2.2 Differentiated retinoblastoma**. These subsections have been removed.

The publisher apologizes for this mistake. The original version of this article has been updated.